Corcept Therapeutics (
#CORT) is a commercial-stage U.S. biopharma focused on cortisol modulators; Corcept is developing
#Relacorilant (a selective GR antagonist), which is under FDA review ahead of its
#PDUFA action date, December 30, 2025.
Cushing’s syndrome is a rare endocrine disorder driven by chronic cortisol excess and is associated with significant cardiometabolic complications, including worsening hypertension. Despite existing treatment options, there remains room for improvement in long-term disease management.
Relacorilant is an investigational therapy in development for endogenous Cushing’s syndrome. In phase3 GRACE trial, approximately 66.7% of patients-maintained blood pressure control during the open label phase.
Corcept maintains a strong liquidity position with a debt-free balance sheet and sizeable cash and marketable securities, providing sufficient capital to support ongoing Phase 2 and Phase 3 programs. The upcoming regulatory and clinical milestones remain financially pivotal, as successful advancement of Relacorilant would accelerate the shift from a single-product revenue model to a multi-asset commercial portfolio. This transition could materially expand operating cash flow and further strengthen the company’s overall financial position.
👉 Follow us for more PDUFA updates.
👉 To learn more, check our pinned post to join our FREE CLOSED BETA
.
#Biotec
h #Stock
